Evonik’s AGM Paves Way for €1.25B Bond Programme and C4 Exit Amid Political Tailwinds
03.06.2026 - 16:33:24 | boerse-global.de
Evonik’s annual general meeting on Tuesday drew attention less for the dividend proposal than for what it signals about the chemical group’s accelerating transformation. Shareholders voted on a package of capital authorisations that, taken together with mounting expectations of a C4 chemicals business sale, point to a decisive push toward higher-margin speciality products.
The board proposed a €1.00 per share dividend, worth roughly €466 million in total, and sought the green light to issue up to €1.25 billion in convertible and warrant bonds. A conditional capital increase of up to 37 million new shares, dubbed Conditional Capital 2026, rounded out the agenda. These tools are not merely precautionary: they give Evonik firepower for acquisitions in a sector that is consolidating fast — the same day the EU Commission cleared the sale of BASF’s paint business to Carlyle for about €7.7 billion.
Outside the boardroom, political developments offered a further tailwind. Germany’s cabinet discussed a circular economy action plan that will channel €260 million from the Climate and Transformation Fund into projects for recovering critical raw materials and recycling batteries, wind turbines and solar modules — all areas where speciality chemicals play a pivotal role. In Brussels, the Commission unveiled the ‘InvestAI’ initiative, aiming to mobilise up to €200 billion for AI, cloud and semiconductors. Evonik’s semiconductor chemicals business stands to benefit from structurally supported demand.
Should investors sell immediately? Or is it worth buying Evonik?
The market is now betting that a divestiture of the C4 chemicals unit will be announced soon after the AGM. Deutsche Bank Research, which reiterated its ‘Hold’ rating and €16 price target on 1 June, sees such a move as a logical next step in Evonik’s portfolio shift away from cyclical base chemicals. Chief Operating Officer Lauren Kjeldsen has been sounding an upbeat note with investors, particularly about the Advanced Technologies segment, where momentum could lift full-year targets above the current guidance range.
On the trading floor, Evonik shares have climbed roughly 26% since January, making it one of the stronger performers in the European chemicals sector this year. The stock changed hands near €16.85 on Tuesday, fractionally below its 50-day moving average of €17.04. Despite the year?to?date rally, the shares still trade about 11% below their level 12 months ago and 13% below the 52-week high of €19.36. Technical indicators flash a note of caution: the relative strength index stands close to 80, suggesting overbought conditions that could cap near?term gains.
The next concrete update on Evonik’s operational performance will come with the second?quarter report in August. By then, the newly approved capital measures and any C4 announcement should offer a clearer picture of whether the company is successfully navigating its shift toward speciality chemicals — and whether the market’s optimism is built on solid ground.
Ad
Evonik Stock: New Analysis - 3 June
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
